Estetrol (E4) for the treatment of moderate to severe vasomotor symptoms in postmenopausal women – Efficacy and safety results from the phase 3 E4COMFORT I multicenter, placebo-controlled trial

Highlights Estetrol (E4) reduced the frequency and severity of vasomotor symptoms from week 4 to week 12 in postmenopausal women in the E4COMFORT I placebo-controlled trial. Significant benefits were observed with both 15 mg and 20 mg doses of E4. E4 treatment was well tolerated, with low discontinuation rates. These findings support the use of E4 in symptomatic postmenopausal women.